
|Articles|November 3, 2015
ICON Partners with iCardiac On Phase I
Advertisement
ICON announced that its clinical research unit in San Antonio is a certified and preferred site in iCardiac’s Early Precision QT Program. The certification enables ICON to offer iCardiac’s Early Precision QT® services for evaluating the cardiac safety of new compounds in Phase I clinical trials. More accurate early QT studies may eliminate the need for later stage TQT studies, potentially saving costs.
Read
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Quantifying the Net Financial Value of Deploying Risk-Based Quality Management
2
ACT Brief: RBQM Financial Value Quantified, Sponsor-Configurable AI Systems, and Basket Trials for Rare Pediatrics
3
ACT Brief: Enterprise Risk Management, Execution Architecture for AI, and Rare Pediatric Regulatory Support
4
ACT Brief: Data Pipeline Fragmentation, Vaccine Trial Pressures, and BTK Degrader Partnership
5




